CA2283490A1 - Vaccin anti-vif - Google Patents

Vaccin anti-vif Download PDF

Info

Publication number
CA2283490A1
CA2283490A1 CA002283490A CA2283490A CA2283490A1 CA 2283490 A1 CA2283490 A1 CA 2283490A1 CA 002283490 A CA002283490 A CA 002283490A CA 2283490 A CA2283490 A CA 2283490A CA 2283490 A1 CA2283490 A1 CA 2283490A1
Authority
CA
Canada
Prior art keywords
fipv
fiv
polynucleotide
deletion
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002283490A
Other languages
English (en)
Inventor
James Charles Neil
Mark Alan Rigby
James Oswald Jarrett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Glasgow
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2283490A1 publication Critical patent/CA2283490A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des formulations de vaccins contre les maladies liées au VIF (virus de l'immunodéficience féline), comportant un polynucléotide PVIF (provirus de l'immunodéficience féline) renfermant un gène pol dysfonctionnel, des fragments du polynucléotide PVIF et leurs utilisations dans la prophylaxie et/ou le traitement de maladies liées au VIF.
CA002283490A 1997-03-11 1998-03-10 Vaccin anti-vif Abandoned CA2283490A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9704977.9A GB9704977D0 (en) 1997-03-11 1997-03-11 FIV vaccine
GB9704977.9 1997-03-11
PCT/GB1998/000715 WO1998040493A1 (fr) 1997-03-11 1998-03-10 Vaccin anti-vif

Publications (1)

Publication Number Publication Date
CA2283490A1 true CA2283490A1 (fr) 1998-09-17

Family

ID=10809020

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002283490A Abandoned CA2283490A1 (fr) 1997-03-11 1998-03-10 Vaccin anti-vif

Country Status (6)

Country Link
EP (1) EP1007687A1 (fr)
JP (1) JP2002501369A (fr)
AU (1) AU6736998A (fr)
CA (1) CA2283490A1 (fr)
GB (1) GB9704977D0 (fr)
WO (1) WO1998040493A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU749059B2 (en) * 1997-12-12 2002-06-20 Cell Genesys, Inc. Therapeutic use of lentiviral vectors
US6764676B1 (en) 1998-08-24 2004-07-20 Pfizer Inc. Compositions and methods for protecting animals from lentivirus-associated disease such as feline immunodeficiency virus
AU773647B2 (en) * 1998-08-24 2004-05-27 Pfizer Products Inc. Compositions and methods for protecting animals from lentivirus-associated disease such as feline immunodeficiency virus
EP1074625A3 (fr) 1999-06-14 2002-01-02 Pfizer Products Inc. ADN vaccin contre le virus de l'immunodéficience chez les félins
US8473414B2 (en) * 2010-04-09 2013-06-25 Visa International Service Association System and method including chip-based device processing for transaction

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9414752D0 (en) * 1994-07-21 1994-09-07 Q One Biotech Ltd Feline gamma-interferon
AU723313B2 (en) * 1996-03-05 2000-08-24 Regents Of The University Of California, The Recombinant live feline immunodeficiency virus and proviral DNA vaccines

Also Published As

Publication number Publication date
JP2002501369A (ja) 2002-01-15
AU6736998A (en) 1998-09-29
WO1998040493A1 (fr) 1998-09-17
EP1007687A1 (fr) 2000-06-14
GB9704977D0 (en) 1997-04-30

Similar Documents

Publication Publication Date Title
EP0969862B1 (fr) Genes synthetiques du gag hiv
JP4749481B2 (ja) 弱毒化された非機能性ｖｉｆタンパク質による免疫応答性誘導
JP5339687B2 (ja) 多種サブタイプｆｉｖワクチン
Hanlon et al. Feline leukemia virus DNA vaccine efficacy is enhanced by coadministration with interleukin-12 (IL-12) and IL-18 expression vectors
US8703145B2 (en) Materials and methods for immunizing against FIV infection
BG64711B1 (bg) Смес от рекомбинантни вектори на ваксина като роlyеnv ваксини за нiv
KR19990087126A (ko) 합성 사람 면역결핍 바이러스 유전자
US6004799A (en) Recombinant live feline immunodeficiency virus and proviral DNA vaccines
JP2009005706A (ja) 抗−ネコ免疫不全ウイルス（ｆｉｖ）ワクチン
US7847085B2 (en) Recombinant HIV-1 gp120 immunogen with three different V3 loops from viruses of different clades
GARDNER Vaccination against SIV infection and disease
JP2009178163A (ja) ネコｃｄ８０、ネコｃｔｌａ−４またはネコｃｄ８６をコードする外来ｄｎａを発現する組換えウイルスおよびその使用
WO1999032147A1 (fr) Immunisation contre l'infection par le virus ebola
CA2283490A1 (fr) Vaccin anti-vif
KR100815888B1 (ko) Ｈｉｖ 보조 단백질을 암호화하는 ｄｎａ 백신
GRANGE et al. Induction of neutralizing antibodies against HTLV-I envelope proteins after combined genetic and protein immunizations in mice
KR20010040618A (ko) 사람 면역결핍 바이러스용 생 백신
US20030118601A1 (en) FIV vaccine
US7658927B2 (en) Materials and methods for immunizing against FIV infection
US20050281844A1 (en) Immunization for Ebola virus infection
US7279168B2 (en) Recombinant virus expressing foreign DNA encoding feline CD86 and uses thereof
KR101059721B1 (ko) 면역원성 조성물 및 의약
by Coadministration Feline Leukemia Virus DNA Vaccine
Moynier et al. Characterization of humoral immune responses induced by immunization with plasmid DNA expressing HIV-1 Nef accessory protein
FR2593519A1 (fr) Vaccin contre le syndrome immunodeficitaire acquis et intermediaires pour la preparation de ce vaccin

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead